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ABSTRACT 
Predicting the onset of psychosis in individuals at-risk is based on robust prognostic 
model building methods including a priori clinical knowledge (also termed clinical-
learning) to preselect predictors or machine-learning methods to select predictors 
automatically. To date, there is no empirical research comparing the prognostic 
accuracy of these two methods for the prediction of psychosis onset. In a first 
experiment, no improved performance was observed when machine-learning methods 
(LASSO and RIDGE) were applied - using the same predictors - to an individualized, 
transdiagnostic, clinically-based, risk calculator previously developed on the basis of 
clinical-learning (predictors: age, gender, age by gender, ethnicity, ICD-10 diagnostic 
spectrum), and externally validated twice. In a second experiment, two refined versions 
of the published model which expanded the granularity of the ICD-10 diagnosis were 
introduced: ICD-10 diagnostic categories and ICD-10 diagnostic subdivisions. 
Although these refined versions showed an increase in apparent performance, their 
external performance was similar to the original model. In a third experiment, the three 
refined models were analysed under machine-learning and clinical-learning with a 
variable event per variable ratio (EPV). The best performing model under low EPVs 
was obtained through machine-learning approaches. The development of prognostic 
models on the basis of a priori clinical knowledge, large samples and adequate events 
per variable is a robust clinical prediction method to forecast psychosis onset in patients 
at-risk, and is comparable to machine-learning methods, which are more difficult to 
interpret and implement. Machine-learning methods should be preferred for high 
dimensional data when no a priori knowledge is available.  
 
Keywords: machine-learning, psychosis, schizophrenia, prognosis, prediction, 
biostatistics. 
INTRODUCTION  
Under standard care, outcomes of psychosis are poor (1). While early interventions at 
the time of a first psychotic episode are associated with some clinical benefits (2), they 
are not effective at preventing relapses (2) or reducing the duration of untreated 
psychosis (DUP) (3); preventive interventions in individuals at clinical high risk for 
psychosis (CHR-P) (4) may be an effective complementary strategy. According to the 
World Health Organization, preventive strategies for mental disorders are based on the 
classification of the prevention of physical illness as universal, selective or indicated 
(targeted at the general public, those with risk factors, and those with minimal signs or 
symptoms of mental disorders respectively, as described by by Gordon et al) and on the 
classic public health classification as primary, secondary or tertiary (seeking to prevent 
the onset of a mental disorder, lower the rate of established disorder or reduce disability 
and relapses respectively (5)). Universal, selective and indicated preventive 
interventions are “included within primary prevention in the public health classification” 
(page 17 in (5)). Since CHR-P individuals show attenuated symptoms of psychosis 
coupled with help-seeking behavior (6) and functional impairments (7), interventions 
in these individuals are defined as indicated primary prevention of psychosis. The 
conceptual and operational framework that characterises the CHR-P paradigm has been 
reviewed elsewhere (8, 9). The empirical success of the CHR-P paradigm is determined 
by the concurrent integration of three core components: efficient detection of cases at-
risk, accurate prognosis and effective preventive treatment (10, 11). The underpinning 
methodology for each of these components is based on risk-prediction models (12). 
Unfortunately, a recent methodological review concluded that most of the CHR-P 
prediction modelling studies are of low quality, largely because they employ stepwise 
variable selection without proper internal and external validation (13). These 
approaches overfit the data (i.e. the model learns the noise instead of accurately 
predicting unseen data (14)), inflate the estimated prediction performance on new cases 
and produce biased prognostic models that result in poor clinical utility (14). Beyond 
stepwise model selection, overfitting can also occur when the number of events (e.g. 
number of at-risk patients who will develop psychosis over time) per variable (e.g. 
degree of freedoms of predictors of psychosis onset in at-risk patients) is low (event-
per-variable, EPV less than 20 (14),(15)). Low EPVs are frequently encountered in the 
CHR-P literature because the onset of psychosis in these samples is an infrequent, 
heterogeneous event (cumulating to 20% at 2-years, (eTable 4 in (16); depending on 
the sampling strategies)(17-20).  
 
A first approach to overcome these caveats is to use a priori clinical-learning or 
knowledge to identify a few robust predictors to be used in risk-prediction models (13): 
it may be possible to use umbrella reviews (i.e. reviews of meta-analyses and systematic 
reviews that incorporate a stratification of the evidence (21)) on epidemiological 
risk/protective factors for psychosis (22)). Because the selection of predictors would be 
limited in number (preserving the EPV(14)) and independent of the data on which the 
model is then tested, overfitting issues would be minimized (13). For example, a recent 
risk estimation model has used a priori clinical-learning to select a few predictors of 
psychosis onset in CHR-P individuals (23). The prognostic model developed was 
robust and has already received several independent external replications (24). A 
second, increasingly popular approach is to bypass any clinical reasoning and instead 
use machine-learning procedures to select the predictors automatically (25): machine-
learning studies have developed and internally validated models to stratify risk 
enrichment in individuals undergoing CHR-P assessment (18) and functional outcomes 
in CHR-P samples (26). Machine-learning methods promise much to the CHR-P field 
because of their potential to assess a large number of predictors and to better capture 
non-linearities and interactions in data; there is great confidence that they will 
outperform model-building based on clinical learning (25). Yet, modern machine-
learning methods may not a panacea (27), particularly because of the lack of empirical 
research comparing machine-learning vs clinical-learning theory-driven methods for 
the prediction of psychosis. The current manuscript advances knowledge by filling this 
gap.  
 
Here we use a transdiagnostic, prognostic model that has been developed by our group 
using a priori meta-analytical clinical knowledge (hereafter clinical-learning) (28). The 
predictors used were collected as part of the clinical routine: age, gender, ethnicity, age 
by gender and ICD-10 index diagnostic spectrum. The model is cheap and 
“transdiagnostic” (29) because it can be applied at scale across several ICD-10 index 
diagnoses to automatically screen mental health trusts. This prognostic model has been 
externally validated twice (28, 30), and is under pilot testing for real-world clinical use 
(11).  
In the first experiment, we apply a machine-learning method to the same 
transdiagnostic individualised prognostic model and test the hypothesis that machine-
learning methods produce models with better prediction accuracy than clinical-learning 
approach when the EPV is adequate. In the second experiment, we expand the 
granularity of the ICD-10 index diagnosis predictor and test the hypothesis that the use 
of more specific diagnostic specifications improves prognostic performance. In the 
third experiment, we test the hypothesis that machine-learning delivers better predicting 
prognostic models than clinical-learning under different models’ specifications, and in 
the specific scenario of low EPVs. Overall, this study provides much needed empirical 
research to guide prediction modelling strategies in early psychosis. 
 
MATERIALS AND METHODS 
Data source 
Clinical register-based cohort selected through a Clinical Record Interactive Search 
(CRIS) tool (31). 
 
Study population 
All individuals accessing South London and Maudsley (SLaM) services in the period 
1st January 2008 to 31st December 2015, and who received a first ICD-10 index primary 
diagnosis of any non-organic and non-psychotic mental disorder (with the exception of 
Acute and Transient Psychotic Disorders, ATPDs) or a CHR-P designation (which is 
available in the whole SLaM through the Outreach And Support In South-London -
OASIS- CHR-P service (32)), were initially considered eligible. The ATPD group is 
diagnostically (33) and prognostically (34) similar to the Brief Limited Intermittent 
Psychotic Symptom (BLIPS) subgroup of the ARMS construct and to the Brief Limited 
Psychotic Symptoms (BIPS) subgroup of the Structured Interview for the Psychosis-
Risk Syndrome (SIPS; for details on these competing operationalisation see eTable 1 
published in (34)) and previous publications on the diagnostic and prognostic 
significance of short-lived psychotic disorders (33, 35, 36). 
Those who developed psychosis in the three months immediately following the first 
index diagnosis were excluded. As previously detailed, this lag period was chosen to 
allow patients sufficient time after their index diagnosis to meet the ICD-10 duration 
criterion for ATPDs. Since we did not employ a structured assessment at baseline (see 
limitation), this lag period was also used to be conservative and exclude individuals 
who were underreporting psychotic symptoms at baseline (false transition to psychosis). 
Ethical approval for the study was granted (31).  
 
Study measures  
The outcome (risk of developing any ICD-10 non-organic psychotic disorder), 
predictors (index ICD-10 diagnostic spectrum, age, gender, ethnicity, and age by 
gender), and time to event were automatically extracted using CRIS (31).  
 
Statistical analyses 
The original study was conducted according to the REporting of studies Conducted 
using Observational Routinely-collected health Data (RECORD) Statement (37).  
 
Experiment 1: Machine-learning vs clinical-learning with adequate EPV for the 
prediction of psychosis 
Development and validation of the original model (M1, diagnostic spectra) followed 
the guidelines of Royston et al., (38) Steyerberg et al. (39) and the Transparent 
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis 
(TRIPOD)(40). The details of model development and external validation have been 
presented previously (28). Briefly, predictors (ICD-10 diagnostic spectrum, age, gender, 
ethnicity, and age by gender interaction) were preselected on the basis of meta-
analytical clinical knowledge (41) as recommended (13). The ICD-10 diagnostic 
spectrum was defined by all of the ten ICD-10 blocks (acute and transient psychotic 
disorders, substance abuse disorders, bipolar mood disorders, non-bipolar mood 
disorders, anxiety disorders, personality disorders, developmental disorders, 
childhood/adolescence onset disorders, physiological syndromes and mental 
retardation (28)), with the exclusion of psychotic and organic mental disorders,  and by 
CHR-P designation (8). Accordingly, the diagnostic predictor of M1 encompassed 11 
different levels. All other predictors together contributed 7 degrees of freedom, for a 
total of 18 degrees of freedom. Cox proportional hazards multivariable complete-case 
analyses were used to evaluate the effects of preselected predictors on the development 
of non-organic ICD-10 psychotic disorders, and time to development of psychosis. 
Non-random split-sample by geographical location was used to create a development 
and external validation dataset (40). Performance diagnostics of individual predictor 
variables in the derivation dataset were explored with Harrell’s C-index (38), which 
can be interpreted as a summary measure of the areas under the time-dependent ROC 
curve (42). A value of C=0.5 corresponds to a purely random prediction whereas C=1 
corresponds to perfect prediction. The model was then externally validated in the 
independent database from SLaM (28), and subsequently in another NHS Trust 
(Camden and Islington)(30). In the SLaM derivation database there were 1001 events 
(EPV 1001/18 =55.61), and in the SLaM validation database there were 1010 events, 
both of which exceed the cut-off of 100 events required for reliable external validation 
studies (43). 
In experiment 1, we tested the hypothesis that even when EPVs are above the 
recommended threshold and predictors are the same, machine-learning would 
outperform clinical-learning methods. Machine learning methods automate model 
building by learning from data with minimal human intervention (44); the best model 
is typically selected by assessing the prediction accuracy of unseen (hold-out) data for 
example using cross-validation methods (45). This is a key difference from classical 
statistical inferential methods, where the quality of a model is assessed by the sample 
used to estimate the model. Machine-learning methods typically introduce a 
regularization term into the model to avoid overfitting, and this term usually imposes a 
penalty on complex models to reduce sample variance (45).  
In our study we used regularized regression methods (also called penalized or shrinkage 
regression methods) as relatively simple, but often powerful machine learning methods 
which compare competitively to more complex machine learning methods like random 
forest or support vector machines (46-48). We chose regularized regression methods to 
enhance interpretability of the final model, in particular compared to models developed 
through clinical learning. It is important for clinicians to interpret prognostic models to 
gain knowledge and to detect their potential biases and limitations in real-world use 
(49). Regularized regression fits generalized linear models, for which the sizes of the 
coefficients are constrained to reduce overfitting. Two common regularized regression 
approaches to be considered in this study are RIDGE (50) and LASSO (51). The 
primary difference between RIDGE and LASSO is that RIDGE regression constrains 
the sum of squares of the coefficients, whereas LASSO constrains the sum of absolute 
values of the coefficients (45). Unlike RIDGE, LASSO shrinks the coefficient to zero 
and thus performs an automatic selection of predictors. The degree of constraint (or 
penalty) is determined by automated computer-intensive grid searches of tuning 
parameters. Because constraints depend on the magnitude of each variable, it is 
necessary to standardize variables.  The final tuning parameter is chosen as the one 
which maximizes a measure of prediction accuracy of unseen (hold-out) data using, for 
example, cross-validation methods (45).  
Therefore, in experiment 1, we applied RIDGE and LASSO to the original 
unregularized Cox regression model in the same database to estimate their apparent and 
external performance (Harrell’s C) in the derivation and validation datasets respectively. 
Their difference was then used to estimate the model’s optimism. 
 
Experiment 2: Diagnostic subdivisions vs diagnostic categories vs diagnostic spectra 
for the prediction of psychosis 
We developed two refined prognostic models, M2 and M3, which differed from the 
original M1 model (diagnostic spectra, e.g. F30-F39 Mood [affective] disorders) by 
employing two expanded definitions of the predictor ICD-10 index diagnosis (the 
strongest predictor of the model (28),(30)). The model M2 (diagnostic categories) 
expanded the M1 model by adopting the 62 ICD-10 diagnostic categories - excluding 
psychotic and organic mental disorders - rather than the broader spectra (e.g. F30 manic 
episode, F31 Bipolar affective disorders etc.). The model M3 (diagnostic subdivisions) 
further expanded the M2 model by including all of the 383 specific ICD-10 diagnostic 
subdivisions of non-organic and non-psychotic mental disorder (e.g. F30.0 hypomania, 
F30.1 mania without psychotic symptoms, F30.2 mania with psychotic symptoms, 
F30.8 other manic episodes, F30.9 manic episode unspecified). From a clinical point of 
view, these refined models reflect the potential utility of specific vs block vs spectrum 
diagnostic formulations for the prediction of psychosis onset in at-risk individuals. The 
two previous independent replications of the original M1 model confirmed that the 
clinicians’ pattern recognition of key diagnostic spectra is useful from a clinical 
prediction point of view. Thus, experiment 2a tested the clinical hypothesis that the use 
of more granular and specific ICD-10 index diagnoses would eventually improve the 
performance of the initial M1 model. The performance of the M1, M2 and M3 models 
was first reported in the derivation and validation dataset. In a subsequent stage, the 
model’s performance (Harrell’s C) was compared across each pair within the external 
validation dataset.  
 
Experiment 3a and 3b. Machine-learning vs clinical-learning under variable EPVs.  
From a statistical point of view, increasing the number of levels of the ICD-10 
diagnoses from M1 (n=10) to M2 (n=62) to M3 (N=383) (plus the CHR designation), 
decreases the EPV from M1 to M2 to M3 respectively, increasing the risk of overfitting 
in unregularized regression models (in particular when the EPV is lower than 20 (52)).  
During experiment 3a, we tested the hypothesis that machine-learning would 
increasingly outperform clinician learning methods with decreasing EPVs. First, we 
compared the apparent performance of M1, M2, M3 in the whole dataset using RIDGE 
and LASSO versus unregularized Cox regression. Second, we compared the internal 
performance of M1, M2 and M3 in the whole dataset using ten-fold cross-validation 
repeated 100 times and taking the median Harrell’s C across the 100 repetitions, again 
using RIDGE, LASSO versus unregularized Cox regression. We used the whole dataset 
because the refined M2 and M3 models have adopted different specifications of the 
ICD-10 diagnoses that were not always present in both derivation and validation 
datasets (in which case it would not have been possible to test the same model). In the 
light of the decreased EPVs we expected RIDGE and LASSO to perform better for M3 
than for M2 than for M1 respectively (45).  
In experiment 3b, we further assessed the impact of varied sample size and degree of 
EPV on the prognostic performance of the model M1 under machine-learning vs 
clinical-learning, without the confounding effect of including more potentially 
informative predictors. We randomly selected samples of different sizes from the 
derivation dataset and then fitted the machine-learning vs clinical-learning approaches 
to these samples. We then assessed the prediction accuracy in the external validation 
dataset. For each sample size, the results of ten repetitions with different random 
samples were averaged, and the median Harrell’s C reported for both the derivation 
(apparent) and validation datasets. Samples sizes were 500, 1000, 2000 and 5000. 
 
All analyses were conducted in STATA 14 and R 3.3.0. using the user-written R 
packages “Coxnet” for the regularized Cox regression models and “Hmisc” to calculate 
Harrell’s C. The difference between two C’s were calculated using the STATA package 
“Somersd” and the R package “Rms”. Compute code is available from the authors (DS) 
upon request. 
 
RESULTS 
Sociodemographic and clinical characteristics of the sample 
91199 patients receiving a first index diagnosis of non-organic and non-psychotic 
mental disorder within SLaM in the period 2008-2015 fulfilled the study inclusion 
criteria and were included in the derivation (33820) or validation (54716) datasets. The 
baseline characteristics of the study population, as well as the derivation and validation 
datasets, are presented in Table 1 (28). The mean follow-up was 1588 days (95% CI 
1582-1595) with no significant differences between the derivation and validation 
datasets.  
 
*** TABLE 1 ABOUT HERE *** 
 
Experiment 1: Machine-learning vs clinical-learning and adequate EPV for the 
prediction of psychosis 
The first analysis compared M1 model performance developed with clinician learning 
(a priori knowledge) against RIDGE and LASSO in both the derivation and validation 
dataset. Harrell's C on derivation set was virtually the same for all three methods on 
both derivation (~ 0.8) and external validation data sets (~ 0.79, Table 2).  
 
*** TABLE 2 ABOUT HERE *** 
 
Experiment 2: Diagnostic subdivisions vs diagnostic categories vs diagnostic 
spectra for the prediction of psychosis 
The database included the majority of the non-organic and non-psychotic ICD-10 
diagnostic categories (57 out of 62, 92% in M2), and diagnostic subdivisions (353 out 
of 383, 92% in M2).  
In the derivation dataset (apparent performance (14)), the M3 model (Harrell’s C 0.833) 
seemed to perform better, than the M2 model (Harrell’s C 0.811) and better than the 
original M1 model (Harrell’s C 0.8). However, this was due to overfitting of the M3 to 
the derivation data, as confirmed by the external validation. In fact, in the validation 
dataset, using all of the ICD-10 diagnostic subdivisions (M3) yielded a comparable 
model performance (about 0.79) to M1 and comparable to the model with the diagnostic 
categories (M2). The latter model (M2) showed statistically significant, superior 
performance compared to M1. However, the magnitude of the improvement of the 
Harrell’s C of 0.007 was too small to be associated with meaningful clinical benefits 
(see Table 3).  
 
*** TABLE 3 ABOUT HERE *** 
 
Experiment 3a and 3b. Prognostic performance using machine-learning vs 
clinical-learning under variable EPVs.  
The results from experiment 3a showed that the clinical-learning and machine-learning 
methods delivered similar apparent prognostic performance (Table 4). After internal 
validation, Harrell’s C slightly decreased, and M1, M2 and M3 models were all similar 
(approximately 0.8). There were again small differences between clinical-learning and 
machine-learning methods, which were more marked as EPV decreased.  
In experiment 3b, Harrell’s C for M1 in the derivation dataset increased with decreasing 
sample size. The increase was larger for clinical-learning (unregularized regression: 
from 0.8 to 0.9), and smaller for machine-learning (RIDGE and LASSO:  0.79 to 0.83, 
Figure 1). The opposite pattern was then seen in the external validation dataset, where 
Harrell’s C for M1 decreased with decreasing sample size. Hence, optimism (the 
difference between Harrell’s C in the apparent sample and with internal validation) 
increased with smaller sizes. As sample size decreased, Harrell’s C decreased slightly 
more when using clinical-learning (unregularized regression: from 0.79 to 0.67 if 
N=500) than when using machine-learning (RIDGE regression: from 0.79 to 0.70 and 
LASSO regression: from 0.79 to 0.69).  
 
*** TABLE 4 and Figure 1 ABOUT HERE *** 
 
DISCUSSION  
This study compared clinical-learning vs machine-learning methods for the prediction 
of individuals at-risk for psychosis. The first experiment indicated that clinical-learning 
methods with a priori selection of predictors and adequate EPV produce robust 
prognostic models that are comparable to those obtained through regularized regression 
machine-learning methods. The second experiment indicated that there is no 
improvement in prognostic accuracy when specific ICD-10 diagnoses are employed 
instead of broad diagnostic spectra. The third experiment indicated that machine 
learning methods can deliver more robust prognostic models that clinical-learning 
methods when the sample size is small and the EPV low, although the benefits are 
modest in magnitude.  
 
The first hypothesis of the current study was that machine-learning methods would 
generally outperform clinical-learning methods using the same set of predictors. This 
was not verified in our study, because when RIDGE and LASSO methods were applied 
to the previously published transdiagnostic individualised risk estimation model, there 
was no substantial difference in prognostic performance. This suggests that when a 
prognostic model is built on strong clinical knowledge, has a large sample and an 
adequate EPV (in this case it was 56), the model can perform very well without the use 
of machine-learning methods. Machine-learning methods are not always necessary to 
obtain an accurate prediction of psychosis onset and do not necessarily improve the 
performance of prognostic models developed on a priori clinical knowledge. For 
example, a recently published supervised machine-learning study failed to demonstrate 
improved prediction of transition to psychosis when using baseline clinical information 
with no a priori knowledge (53), suggesting that a priori clinical knowledge remains 
very important for developing good prognostic models. Given a comparable accuracy, 
models developed through clinical-learning tend to be more straightforward and thus 
more likely to be interpreted, assessed and accepted, and implemented in clinical care 
(see below).  
Our second hypothesis was that adding more information to the model by expanding 
the granularity of the ICD-10 index diagnosis would improve prognostic performance. 
The results showed no prognostic benefit to using specific ICD-10 diagnoses compared 
to broad diagnostic spectra for the prediction of psychosis in secondary mental health 
care. The diagnostic spectra employed by the original version of the transdiagnostic 
individualised risk calculator (28) are robust because they originate in prototypical 
descriptions containing a core phenomenological structure (gestalt) of the disorder and 
its polysymptomatic manifestations (29). Examination of overlaps of etiological factors 
between disorders confirms that higher level broad diagnostic constructs may be more 
valid and clinically useful categories than specific diagnostic categories (54). The 
prognostic utility of the ICD-10 diagnostic spectra is also in line with recent meta-
analytical findings indicating that diagnostic spectra (e.g. psychosis) are relatively 
stable at the time of a first episode of psychosis (55). These diagnostic spectra are 
certainly not optimal, yet they do not present an insuperable barrier to scientific 
progress (56), and in terms of scalability in secondary mental health care (57) have yet 
to be beaten by other predictors of psychosis onset. Conversely, available clinical 
evidence indicates that the specific ICD-10 diagnoses are unreliable and unstable, and 
this may explain why their use is associated with overfitting problems and lack of 
prognostic benefits (55). It is also possible that the small number of cases observed in 
some specific diagnostic categories may interfere with the efficacy of machine learning 
approaches.  
The third hypothesis was that LASSO and RIDGE would perform better in the presence 
of either unstable (such as the specific ICD-10 diagnoses) or redundant predictors, or 
infrequent events (low EPV); RIDGE is generally better with a small number of 
unstable predictors, and LASSO with a large number. This hypothesis was confirmed: 
the best performing model under low EPV and unstable predictors was obtained 
through machine-learning approaches (13). However, the improvement in prognostic 
performance was modest, indicating that if strong predictors are known in advance 
through clinical-learning, it may be difficult to improve the model by adding many 
other variables which are more likely to be interpreted as noise, even when using 
penalized regression machine-learning methods. Notably, our study tested only two 
simple machine learning methods (RIDGE and LASSO), so we cannot exclude the 
possibility that prognostic improvements may have been larger if more complex 
machine learning methods (such as random forest or support vector machines for 
survival) have been used (58, 59). However, Ploeg, Austin, and Steyerberg 
demonstrated that the development of robust models by machine-learning methods 
requires more cases-per-candidate predictors than traditional statistical methods when 
the dimensionality is not extremely high(27). Interestingly, even if large data sets are 
available, complex machine learning methods (i.e. random forests) only showed only 
minor improvement (at the expense of reduced interpretability and no automatic 
variable selection) over simple statistical models (27). This view was pragmatically 
supported by a recent systematic review which compared random forests, artificial 
neural networks, and support vector machines models to logistic regression. Across 282 
comparisons, there was no evidence of superior performance of machine-over clinical-
learning for clinical prediction modelling (60).  
Not surprisingly,  the prognostic tools used to date in the real world clinical routine of 
CHR-P services are still based on clinical-learning (23, 28). However, in the current 
study, we could not test whether the addition of new multimodal predictors - beyond 
the clinical and sociodemographic ones - would improve the prognostic accuracy of 
psychosis onset. Some studies have suggested that the combination of clinical 
information with structural neuroimaging measures (such as gyrification and 
subcortical volumes) could improve prognostic accuracy (61). However, available 
studies failed to provide convincing evidence that multimodal predictors under machine 
learning can substantially improve prognostic accuracy for predicting psychosis onset 
in patients at risk (62, 63). Furthermore, complex models based on multimodal domains 
are constrained by logistical and financial challenges that can impede the ability to 
implement and scale these models in the real world. A potentially promising solution 
may be to adopt a sequential testing assessment to enrich the risk in a stepped 
framework, as demonstrated by our group with a simulation meta-analysis (64). 
Interestingly, a recent machine-learning study on patients at-risk for psychosis 
confirmed that adding neuroimaging predictors to clinical predictors produced a 1.9-
fold increase in prognostic certainty in uncertain cases of patients at-risk for psychosis 
(26).  
Our study provides some conceptual and broad implications; although machine 
learning methods have attracted high expectations in the field (25, 65, 66), the 
enthusiasm may not be entirely substantiated in the field of psychosis. First, we have 
demonstrated that if robust a priori clinical knowledge is available, and if there are 
large sample sizes and EPVs, clinical-learning is a valid method to develop robust 
prognostic models. Clearly, a priori clinical knowledge may not always be available, 
and high dimensional databases with large sample sizes or strong signal to noise ratio 
may be needed to address the complexity of mental disorders. Under those 
circumstances, machine-learning methods can produce more robust prognostic models. 
Our study also provides support for this situation where detailed clinical information is 
not available; machine learning methods were able to identify models of similar 
prediction accuracy.  
 
Second, the methodological, empirical and conceptual limitations of machine learning 
in psychiatry have not been completely addressed. Overoptimistic views, excessive 
faith in technology (67) and lack of knowledge of limitations of a specific methodology 
can lead to unrealizable promises (68). While machine learning methods can potentially 
achieve good predictive accuracy in high dimensional data when there is poor a priori 
knowledge, they tend to deliver ‘black-box’ classifiers that provide very limited 
explanatory insights into psychosis onset (69). This is a fundamental limitation: without 
direct interpretability of a prognostic procedure, implementation in clinical practice 
may be limited (68). To have high impact and be adopted on a broader scale, a 
prognostic model must be accepted and understood by clinicians. Prediction models 
developed through clinical-learning are traditionally better understood by clinicians 
than machine learning models (70), while machine-learning models are challenging to 
evaluate and apply without a basic understanding of the underlying logic on which they 
are based (71). A partial solution may be to incorporate a priori knowledge into 
machine-learning approaches(72). Because of these issues, some authors argue that 
clinical-learning and reasoning will become even more critical to distil machine-
learning and data-driven knowledge (73), and preliminary studies suggest that the 
combined use of theory-driven and machine learning approaches can be advantageous 
(74). There is a trend towards converting “big data” into “smart data” through 
contextual and personalised processing, allowing clinicians and stakeholders to make 
better decisions; our study supports such an approach (75).  
 
Third, an additional pragmatic limitation is that for prediction models to ultimately 
prove useful, they must demonstrate impact (76) - their use must generate better patient 
outcomes (70). Impact studies for machine-learning approaches in patients at-risk for 
psychosis are lacking. Rigorous tests on independent cohorts are critical requirements 
for the translation of machine-learning research to clinical applications (77). To our 
knowledge, the only study that has estimated the potential clinical benefit associated 
with the use of a prognostic model in secondary mental health care is our 
transdiagnostic individualised risk calculator analysis, which was based on clinical-
learning (28). A recent review observed that although there are thousands of papers 
applying machine-learning algorithms to medical data, very few have contributed 
meaningfully to clinical care (78). Another recent empirical study focusing on the 
clinical impact of machine-learning in early psychosis concluded that the current 
evidence for the diagnostic value of these methods and structural neuroimaging should 
be reconsidered toward a more cautious interpretation(79). 
 
 
CONCLUSIONS 
Developing prognostic models on the basis of a priori clinical knowledge, large 
samples and adequate events per variable is a robust clinical prediction method for 
forecasting psychosis onset in patients at-risk. Under these circumstances, the 
prognostic accuracy is comparable to that obtained through machine-learning methods, 
which are more difficult to interpret and may present additional implementation 
challenges. The use of diagnostic spectra for transdiagnostic prediction of psychosis in 
secondary mental health care offers superior prognostic accuracy than the use of more 
specific diagnostic categories. Machine-learning methods should be considered in cases 
of high dimensional data when no a priori knowledge is available.  
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Table 1. Sociodemographic characteristics of the study population, including the derivation and validation dataset(28) 
     
Derivation dataset 
(Lambeth and 
Southwark, n=33820) 
Validation dataset 
(Croydon and 
Lewisham, n=54716)  
      Mean SD Mean SD   
Age (years)(a)   34.4 18.92 31.98 18.54   
      Count % Count %   
Gender         
 Male   17303 48.81 27302 49.9   
 Female   16507 51.16 27398 50.07   
 Missing   10 0.03 16 0.03   
Ethnicity         
 Black   6879 20.34 7023 12.84   
 White   18627 55.08 35392 64.68   
 Asian   1129 3.34 2608 4.77   
 Mixed   1306 3.86 1957 3.58   
 Other   3466 10.25 2084 3.81   
 Missing   2413 7.13 5652 10.33   
ICD-10 Index spectrum diagnosis          
 CHR-P (a)    314 0.93 50 0.09   
 
Acute and transient psychotic 
disorders   553 1.64 725 1.33   
 Substance use disorders   7149 21.14 6507 11.89   
 Bipolar mood disorders   950 2.81 1526 2.79   
 Non-bipolar mood disorders   6302 18.63 8841 16.16   
 Anxiety disorders   8235 24.35 15960 29.17   
 Personality disorders   1286 3.8 2116 3.87   
 Developmental disorders   1412 4.18 3706 6.77   
 
Childhood/adolescence onset 
disorders   4200 12.42 9629 17.6   
 Physiological syndromes   2555 7.55 4424 8.09   
 Mental retardation   864 2.55 1232 2.25   
(a) Not an ICD-10 Index spectrum diagnosis 
Table 2. Experiment 1: Prognostic accuracy (Harrell’s C) for the original model (M1, diagnostic spectra) developed through Clinical-
learning (a priori clinical knowledge) vs machine learning (LASSO and RIDGE). The EPV is >20 (55.6). 
  
METHOD DERIVATION DATA SET 
(N=33,820) 
VALIDATION DATA SET 
(N=54,716) 
OPTIMIS
M 
 Harrell’s C SE 95% C.I. Harrell’s 
C 
SE 95% C.I.   
UNREGULARIZED  0.800 0.008 0.784 - 0.816 0.791 0.008 0.775 - 
0.807 
0.009 
LASSO 0.798 0.008 0.782 - 0.814 0.789 0.008 0.773 - 
0.805 
0.009 
RIDGE 0.810 0.008 0.794 - 0.826 0.788 0.008 0.772 - 
0.804 
0.022 
Table 3. Experiment 2: Prognostic performance of the revised models in the 
derivation dataset and the validation dataset, and their comparative performance.   
Model Type of clustering of 
ICD-10 index 
diagnoses 
Harrell's C SE 95%CI 
Derivation dataset 
M1 Diagnostic spectra  0.800 0.008 0.784 0.816 
M2 Diagnostic categories 0.811 0.008 0.795 0.824 
M3 Diagnostic subdivisions 0.833 0.008 0.821 0.847 
Validation dataset 
M1 Diagnostic spectra  0.791 0.008 0.776 0.807 
M2 Diagnostic categories 0.797 0.008 0.782 0.812 
M3 Diagnostic subdivisions  0.792 0.008 0.776 0.808 
M2-M1  0.006 0.003 0.001 0.012 
M3-M1  0.001 0.005 -0.009 0.011 
M3-M2   -0.005 0.005 -0.015 0.004 
All models include age, gender, age by gender, ethnicity and ICD-10 index 
diagnosis (refined as specified in the methods)  
Table 4 Experiment 3a. Prognostic performance using machine-learning vs clinical-learning under variable EPVs. Upper part of the table: 
apparent performance of M1-M3 models in the whole dataset. Bottom part of the table: internal performance in the whole dataset using nested 
10-fold CV and taking median values with 100 repetitions.  
Apparent 
performance M1 (diagnostic spectra) M2 (diagnostic categories) M3 (diagnostic subdivisions) 
  
Unregularized 
Cox Regression LASSO RIDGE 
Unregularized 
Cox Regression LASSO RIDGE 
Unregularized 
Cox Regression LASSO RIDGE 
C index 0.800 0.793 0.790 0.811 0.799 0.803 0.827 0.812 0.813 
SE 0.005 0.005 0.006 0.005 0.005 0.005 0.005 0.005 0.005 
 
Internal validation 
performance M1 (diagnostic spectra) M2 (diagnostic categories) M3 (diagnostic subdivisions) 
  
Unregularized 
Cox Regression LASSO RIDGE 
Unregularized 
Cox Regression LASSO RIDGE 
Unregularized 
Cox Regression LASSO RIDGE 
C index 0.799 0.794 0.790 0.804 0.795 0.795 0.805 0.793 0.797 
SE 0.017 0.017 0.017 0.017 0.017 0.017 0.017 0.017 0.017 
Events 2011 2011 2011 
Degrees of freedom of 
predictors 18 63 226 
EPV 111.7 31.9 8.9 
EPV, Events Per Variables, calculated as the number of transitions to psychosis over the degrees of freedom of predictors. Categorical 
predictors are counted as the number of indicator categories they consist of (i.e. number of categories - 1). 
 
  
 
Figure 1. Experiment 3b. Clinical-learning (unregularized regression) vs machine learning (LASSO and RIDGE) for the original model M1 
with random sampling of varying sample sizes and decreasing EPV.  
 
